Table 1.
The characteristics of included studies.
| Author, country, year | Study type | Total patients (n) | CMV monitoringmethod | Incidence of CMV infection/CMV reactivation (n) | Incidence of CMV disease (n) | Graft rejection (n) | OpportunisticInfections (n) | Graft loss (n) | Mortality (n) | Follow up (months) | NOS | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prophylaxis | Preemptive | Prophylaxis | Preemptive | Prophylaxis | Preemptive | Prophylaxis | Preemptive | Prophylaxis | Preemptive | Prophylaxis | Preemptive | Prophylaxis | Preemptive | |||||
| Singh et al, USA, 2020 (9) | RCT | 105 | 100 | CMV PCR assay | NA | NA | 20 | 9 | 33 | 37 | 33 | 36 | 2 | 4 | 20 | 15 | >12 months | 9 |
| Liu et al, USA, 2018 (11) | Prospective | 156 | 160 | CMV PCR assay | NA | 114 | 3 | 3 | 25 | 31 | 17 | 17 | 3 | 5 | 12 | 8 | >12 months | 8 |
| Bodro et al, Spain, 2012 (12) | Retrospective | 35 | 39 | pp65 antigen assay | 3 | 15 | 5 | 19 | 6 | 6 | 1 | 4 | NA | NA | 2a | 5a | >12 months | 9 |
| Simon et al, Germany, 2016 (19) | Retrospective | 60 | 68 | CMV PCR assay | 1 | 2 | 2 | 14 | NA | NA | 40 | 46 | 10 | 7 | 18 | 27/67b | >12 months | 7 |
| Mengelle et al, France, 2015 (20) | Retrospective | 56 | 73 | CMV PCR assay | 18 | 42 | 4 | 7 | 13 | 35 | NA | NA | NA | NA | 11 | 17 | >12 months | 7 |
| Scott et al, Australia, 2011 (21) | Retrospective | 39 | 25 | CMV PCR assay | 12 | 12 | 3 | 0 | NA | NA | NA | NA | NA | NA | NA | NA | >12 months | 6 |
| Onor et al, USA, 2013 (22) | Retrospective | 61 | 48 | CMV PCR assay | 17 | 24 | 0 | 48 | 5 | 3 | 35 | 34 | NA | NA | 3 | 1 | 6-months | 6 |
| Lindner et al, Germany, 2016 (23) | Retrospective | 21 | 26 | CMV PCR assay | 1 | 3 | 1 | 1 | 2 | 2 | NA | NA | NA | NA | 1 | 7 | >12 months | 9 |
| Nicastro et al, Italy, 2016 (24) | Retrospective | 16 | 100 | CMV PCR assay | 10 | 61 | 1 | 3 | 6 | 31 | NA | NA | 3 | 4 | 2 | 3 | >60 months | 6 |
| Kim et al, Korea, 2012 (25) | Retrospective | 281 | 281 | . CMV PCR assay | 42 | 32 | NA | NA | NA | NA | NA | NA | NA | NA | 37 | 52 | >12 months | 7 |
| Lianghui et al, China, 2004 (10) | Retrospective | 41 | 48 | pp65 antigen assay | 25 | 26 | 5 | 15 | 16 | 23 | NA | NA | NA | NA | 0 | 1 | >12 months | 7 |
CMV, Cytomegalovirus; PCR, Polymerase Chain Reaction; pp65, Phosphoprotein 65; NOS, Newcastle-Ottawa Quality Assessment Scale. , NA, not available.
acase fatality.
bone censored case.